Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Amortizatization of Intangibles (2022 - 2025)

Historic Amortizatization of Intangibles for InMed Pharmaceuticals (INM) over the last 4 years, with Q3 2025 value amounting to $103478.0.

  • InMed Pharmaceuticals' Amortizatization of Intangibles rose 1446.55% to $103478.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $334962.0, marking a year-over-year decrease of 1096.05%. This contributed to the annual value of $321885.0 for FY2025, which is 1637.57% down from last year.
  • Per InMed Pharmaceuticals' latest filing, its Amortizatization of Intangibles stood at $103478.0 for Q3 2025, which was up 1446.55% from $78330.0 recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Amortizatization of Intangibles ranged from a high of $103478.0 in Q3 2025 and a low of $75876.0 during Q4 2024
  • Moreover, its 4-year median value for Amortizatization of Intangibles was $93085.0 (2023), whereas its average is $91152.5.
  • Over the last 5 years, InMed Pharmaceuticals' Amortizatization of Intangibles had its largest YoY gain of 1446.55% in 2025, and its largest YoY loss of 1932.56% in 2025.
  • Quarter analysis of 4 years shows InMed Pharmaceuticals' Amortizatization of Intangibles stood at $90389.0 in 2022, then grew by 2.98% to $93085.0 in 2023, then decreased by 18.49% to $75876.0 in 2024, then surged by 36.38% to $103478.0 in 2025.
  • Its last three reported values are $103478.0 in Q3 2025, $78330.0 for Q2 2025, and $77278.0 during Q1 2025.